ArticleResearch square2025
Does frailty modulate the predictive value of performance status in older adults living with cancer?
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Background: Cancer treatments are not a one-size-fits-all approach, treatment options are rarely studied in aging individuals, leading to worse outcomes related to increased vulnerability in this group of patients. Aims: Since frailty has shown the ability to modify outcomes, our study aims to assess if frailty modifies the association between performance status and days in bed with mortality risk in older adults with cancer. Methods: Our study is a secondary analysis of the Mexican Health and Aging Study, a cohort with a representative sample of individuals aged 50 years or older, with a baseline assessment in 2001 and follow-up data available for the years 2003, 2012, 2015, 2018 and 2021. We extracted the baseline variables from the main questionnaires, and the next-of-kin questionnaires were employed for information regarding mortality. We used Cox regression and Kaplan-Meier curves for survival analysis. Results: Our sample was composed of 318 individuals, with a mean age of 68.02 years (± SD 10.78), and 62.57% were women. Cox regression revealed that age was a significant risk factor for mortality in frail patients but not in those with low frailty levels. Discussion: in settings where access to a geriatric assessment is limited or would significantly delay cancer-specific therapies, assessing frailty might improve the accuracy of those available cancer prognostic tools that might underperform in frail older adults. Conclusions: Frailty evaluation improves the assessment of older adults living with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.